| 1  | Incidence and risk factors of omicron variant SARS-CoV-2 breakthrough   |
|----|---|
| 2  | infection among vaccinated and boosted individuals.   |
| 3  |   |
| 4  | Fabiola M. Moreno-Echevarria <sup>1</sup> , Mathew T. Caputo <sup>2</sup> , Daniel M. Camp <sup>1&amp;</sup> , Susheel Reddy <sup>2&amp;</sup> , Chad |
| 5  | J. Achenbach <sup>1-4</sup> 1*  |
| 6  |   |
| 7  |   |
| 8  | <sup>1</sup> Robert J. Havey Institute for Global Health, Feinberg School of Medicine, Northwestern   |
| 9  | University; <sup>2</sup> Department of Medicine, Division of Infectious Diseases, Feinberg School of  |
| 10 | Medicine, Northwestern University; <sup>3</sup> Department of Biomedical Engineering, McCormick School  |
| 11 | of Engineering, Northwestern University; <sup>4</sup> Department of Preventive Medicine, Feinberg School  |
| 12 | of Medicine, Northwestern University  |
| 13 | *Corresponding author: Chad J. Achenbach, M.D., M.P.H., Havey Institute for Global Health,  |
| 14 | Feinberg School of Medicine, Northwestern University, 710 N Lake Shore Drive, Chicago, IL   |
| 15 | 60611, email: c-achenbach@northwestern.edu, phone: 312-503-8810, fax: 312-503-8800  |
| 16 | These authors contributed equally to this work  |
| 17 | <sup>&amp;</sup> These authors also contributed equally to this work.   |
| 18 |   |
| 19 |   |
| 20 |   |
| 21 |   |
| 22 |   |

## 23 Abstract

Background: SARS-CoV-2 vaccines have been shown to be safe and effective against infection and severe COVID-19 disease worldwide. Certain co-morbid conditions cause immune dysfunction and may reduce immune response to vaccination. In contrast, those with co-morbidities may practice infection prevention strategies. Thus, the real-world clinical impact of co-morbidities on SARS-CoV-2 infection in the recent post-vaccination period is not well established. We performed this study to understand the epidemiology of Omicron breakthrough infection and evaluate associations with number of comorbidities in a vaccinated and boosted population.

31 Methods and Findings: We performed a retrospective clinical cohort study utilizing the Northwestern Medicine Enterprise Data Warehouse. Our study population was identified as fully vaccinated adults with 32 at least one booster. The primary risk factor of interest was the number of co-morbidities. Our primary 33 outcome was incidence and time to first positive SARS-CoV-2 molecular test in the Omicron predominant 34 era. We performed multivariable analyses stratified by calendar time using Cox modeling to determine 35 36 hazard of SARS-CoV-2. In total, 133,191 patients were analyzed. Having 3+ comorbidities was associated with increased hazard for breakthrough (HR=1.2 CI 1.2-1.6). During the second half of the study, having 2 37 comorbidities (HR= 1.1 95% CI 1.02-1.2) and having 3+ comorbidities (HR 1.7, 95% CI 1.5-1.9) were 38 39 associated with increased hazard for Omicron breakthrough. Older age was associated with decreased hazard in the first 6 months of follow-up. Interaction terms for calendar time indicated significant changes 40 in hazard for many factors between the first and second halves of the follow-up period. 41

42 Conclusions: Omicron breakthrough is common with significantly higher risk for our most vulnerable 43 patients with multiple co-morbidities. Age related behavioral factors play an important role in breakthrough 44 infection with the highest incidence among young adults. Our findings reflect real-world differences in 45 immunity and exposure risk behaviors for populations vulnerable to COVID-19.

46

## 47 Introduction

| 48 | Vaccines against SARS-COV-2, have been developed and shown in numerous studies to be safe                    |
|----|--|
| 49 | and highly effective at reducing SARS-CoV-2 infection and COVID-19 disease [1-3]. However, clinical          |
| 50 | trials and population-based observational studies excluded or did not compare certain groups at highest risk |
| 51 | for severe outcomes of COVID-19. The impact of age and burden of immune disorders or certain chronic         |
| 52 | conditions on vaccine effectiveness (including boosting) in terms of acquisition of infection, has not been  |
| 53 | adequately studied in our current era dominated by omicron SARS-CoV-2 subvariants.                           |

Although there have been impressive advances in our understanding of protective immunity against 54 COVID-19 after vaccination and natural infection, risk of infection is not completely understood for our 55 most vulnerable patients including individuals who are immune compromised (age, HIV, malignancies, 56 57 solid organ transplant, stem cell transplant) or have chronic illnesses (diabetes, obesity, chronic liver 58 disease, and chronic kidney disease). SARS-CoV-2 vaccines stimulate both B and T cell responses to virus spike protein to elicit an effective immune response [4]. Those with dysfunctional immunity have been 59 observed to have lower responses to vaccination with antibody titers as indicators of immunogenicity [5]. 60 Questions remain about how lower immunogenicity translates into diminished clinical effectiveness of 61 COVID-19 vaccines in real world populations with different co-morbidities. Individuals who have chronic 62 disease, advanced age, and/or immunodeficiencies may be at higher risk for breakthrough infection due to 63 poor vaccine response (defined as COVID-19 infection after completion of all require doses with a typical 64 2-week lag period) [6]; however, they may also practice better infection prevention such as mask wearing, 65 avoiding travel or large gatherings, and social distancing [7]. 66

The incidence of SARS-CoV-2 breakthrough infection is an increasingly important issue worldwide, with vulnerable populations at high risk of infection at a time when vaccine-induced immunity may not be fully optimized. To gain insight into this issue and to inform public health decision making, our

study aimed and was able to determine the incidence and risk factors associated with SARS-CoV-2
breakthrough infection in the Omicron-variant era among vaccinated and boosted individuals.

## 72 Methods

#### 73 Study Design

We performed a clinical cohort study of breakthrough infection in the first year of SARS-CoV-2 Omicron-variant era (January 1, 2022, until December 31, 2022) among fully vaccinated and boosted adults (18 years and older) as per CDC/FDA vaccine guidelines for COVID-19 [8], All demographic, lab, vaccine, and comorbidity data were collected from the Northwestern Medicine (NM) Enterprise Data Warehouse (EDW)[9]. Each participant had a unique study identifier and protected health information was stored separately with access limited to the principal investigator.

#### 80 Population & Definitions

We included adults that were boosted prior to the Omicron era, which we defined as those who received at least 3 (first dose mRNA) or 2 (first dose J&J) SARS-CoV-2 vaccine doses prior to December 15, 2021. To include a representative population that was likely to have SARS-CoV-2 testing performed within the NM system, we only included patients if they had at least two medical system visits (including inpatient, outpatient, telemedicine, and lab testing) at least 180 days apart between January 1, 2020, and December 15, 2021.

We observed individuals in this cohort from January 1, 2022, to December 31, 2022, for incident breakthrough infection with SARS-CoV-2 as our primary outcome defined as the first positive SARS-CoV-2 PCR test performed at an NM facility after January 1, 2022. Patients who tested positive for SARS-CoV-2 after their most recent booster dose but prior to January 1, 2022, were excluded. Data was accessed throughout this study period. Comorbidities of interest (diabetes, obesity, solid organ transplant, stem cell

transplant, HIV, hematologic malignancy, chronic liver disease, and chronic kidney disease) were identified
using ICD9/ICD10 coding.

#### 94 Statistical Analysis

Descriptive statistics, including median (IOR) and counts (%), were calculated for patient 95 characteristics and compared between those with and without breakthrough SARS-CoV-2 infection during 96 the study period. We calculated cumulative incidence as the number of breakthrough infections divided by 97 98 the total number of those at risk (no prior breakthrough infection during study and not right censored) and plotted these curves with 95% confidence intervals assuming normality over the study period. Patients were 99 right censored in cases of death, additional SARS-CoV-2 vaccines, or loss to follow-up. Loss to follow-up 100 101 was defined as 90 days without a visit at NM (outpatient visit, hospital admission, or laboratory testing). We performed Cox regression modeling to determine proportional hazards of breakthrough infection with 102 the following covariates: age, sex, race, ethnicity, time from booster dose to study period start, and number 103 of comorbidities. We included the overall number of comorbidities rather than the specific comorbidities 104 themselves as this study aimed to measure associations with overall health, not individual disease 105 epidemiology. The proportional hazards assumption was assessed graphically with cumulative incidence 106 curves for each covariate. For covariates that violated this assumption, interaction terms for calendar time 107 108 were considered. Multicollinearity was assessed with generalized variance inflation factors (GVIFs). If  $(\text{GVIF}^{1/(2 \cdot \text{DF})})^2 > 3$ , removal of those variables from the model was considered. Linearity of log hazards for 109 continuous covariates was examined with martingale residuals from the fitted model. The car, survival and 110 *tidycmprsk* packages in R 4.2.3 software were used for statistical analysis and plot production [10-13]. 111

### **112 Results**

113 Clinical and demographic characteristics of the cohort included and analyzed are presented in 114 **Table 1**. In total, there were 133,191 patients in the cohort with a median (IQR) age of 61 years (47, 72) 115 63% female sex, 84% white, 95 % Non-Hispanic or Latino ethnicity, and 77% with any comorbid condition.

- 116 Overall, 99% of individuals received mRNA SARS-CoV-2 booster. One booster dose vaccine was
- administered to 99.2% of individuals and 0.8% had received more than one booster dose.

| Characteristic               | Overall,        | No Breakthrough                    | Breakthrough                               |
|------------------------------|-----------------|------------------------------------|--|
|                              | N = 133,191     | <b>Infection</b> , N = $125,287^1$ | <b>Infection</b> , N<br>7,904 <sup>1</sup> |
| Age                          |                 |                                    |  |
| 18-39                        | 19,936 (15%)    | 18,189 (15%)                       | 1,747 (22%)                                |
| 40-59                        | 41,874 (31%)    | 39,071 (31%)                       | 2,803 (35%)                                |
| 60-79                        | 58,857 (44%)    | 56,105 (45%)                       | 2,752 (35%)                                |
| 80+                          | 12,524 (9.4%)   | 11,922 (9.5%)                      | 602 (7.6%)                                 |
| Sex                          |                 |                                    |  |
| Male                         | 49,846 (37%)    | 46,992 (38%)                       | 2,854 (36%)                                |
| Female                       | 83,345 (63%)    | 78,295 (62%)                       | 5,050 (64%)                                |
| Race                         |                 |                                    |  |
| White                        | 112,542 (84%)   | 106,077 (85%)                      | 6,465 (82%)                                |
| Asian                        | 6,453 (4.8%)    | 5,930 (4.7%)                       | 523 (6.6%)                                 |
| Black or African American    | 8,206 (6.2%)    | 7,729 (6.2%)                       | 477 (6.0%)                                 |
| Other                        | 5,990 (4.5%)    | 5,551 (4.4%)                       | 439 (5.6%)                                 |
| Hispanic, Latino, or Spanish | 7,055 (5.3%)    | 6,400 (5.1%)                       | 655 (8.3%)                                 |
| First Vaccine Type           |                 |                                    |  |
| Adenovirus vector            | 4,194 (3.1%)    | 3,984 (3.2%)                       | 210 (2.7%)                                 |
| mRNA                         | 128,997 (97%)   | 121,303 (97%)                      | 7,694 (97%)                                |
| Booster Type                 |                 |                                    |  |
| Adenovirus vector            | 835 (0.6%)      | 782 (0.6%)                         | 53 (0.7%)                                  |
| mRNA                         | 132, 279 (99 %) | 124,434 (99%)                      | 7,845 (99%)                                |

#### 118 Table 1: Characteristics of patients overall, with and without breakthrough SARS-CoV-2 infection.

| Other                   | 6 (<0.1%)     | 6 (<0.1%)     | 0 (0%)      |
|-------------------------|---------------|---------------|-------------|
| Unknown                 | 71 (<0.1%)    | 65 (<0.1%)    | 6 (<0.1%)   |
| Vaccine Status          |               |               |             |
| Boosted 2+ Times        | 1,025 (0.8%)  | 982 (0.8%)    | 43 (0.5%)   |
| Boosted Once            | 132,166 (99%) | 124,305 (99%) | 7,861 (99%) |
| Days since booster      | · · · · · ·   |               |             |
| 15-29                   | 20,431 (15%)  | 19,210 (15%)  | 1,221 (15%) |
| 30-59                   | 50,458 (38%)  | 47,625 (38%)  | 2,833 (36%) |
| 60-89                   | 43,353 (33%)  | 40,596 (32%)  | 2,757 (35%) |
| 90+                     | 18,949 (14%)  | 17,856 (14%)  | 1,093 (14%) |
| Diabetes mellitus       | 20,958 (16%)  | 19,739 (16%)  | 1,219 (15%) |
| Solid Organ Transplant  | 860 (0.6%)    | 779 (0.6%)    | 81 (1.0%)   |
| HIV/AIDS                | 6,113 (4.6%)  | 5,680 (4.5%)  | 433 (5.5%)  |
| Chronic Liver Disease   | 4,665 (3.5%)  | 4,343 (3.5%)  | 322 (4.1%)  |
| Chronic Renal Disease   | 15,084 (11%)  | 14,174 (11%)  | 910 (12%)   |
| End Stage Renal Disease | 940 (0.7%)    | 835 (0.7%)    | 105 (1.3%)  |
| Stem Cell Transplant    | 428 (0.3%)    | 408 (0.3%)    | 20 (0.3%)   |
| Asthma                  | 16,546 (12%)  | 15,308 (12%)  | 1,238 (16%) |
| COPD                    | 5,098 (3.8%)  | 4,753 (3.8%)  | 345 (4.4%)  |
| Cancer                  | 22,839 (17%)  | 21,701 (17%)  | 1,138 (14%) |
| Hypertension            | 60,112 (45%)  | 56,742 (45%)  | 3,370 (43%) |
| Hematologic Malignancy  | 2,936 (2.2%)  | 2,762 (2.2%)  | 174 (2.2%)  |
| Immunodeficiencies      | 11,865 (8.9%) | 11,113 (8.9%) | 752 (9.5%)  |
| Obesity                 | 45,046 (34%)  | 42,172 (34%)  | 2,874 (36%) |

| 0                                | 30,359 (23%) | 28,524 (23%) | 1,835 (23%) |
|----------------------------------|--------------|--------------|-------------|
| 1                                | 32,422 (24%) | 30,495 (24%) | 1,927 (24%) |
| 2                                | 27,528 (21%) | 25,971 (21%) | 1,557 (20%) |
| 3+                               | 42,882 (32%) | 40,297 (32%) | 2,585 (33%) |
| <sup>1</sup> n (%); Median (IQR) |              |              |             |

119

Of the total cohort, 7,904 (5.9%) tested positive for SARS-Cov-2 infection by PCR during the study period in a median (IQR) of 135 (34, 196) days. The infections occurred in a median (IQR) of 196 (115, 260) days after a booster dose of vaccine. Approximately 31% of the total cohort was right-censored due to loss to follow-up, 21% due to additional boosters, and 0.4% due to death.

The proportional hazards assumption in Cox regression was violated for the following covariates: age, race, days since vaccination, and number of comorbidities. Graphical assessment indicated that significant changes in incidence rate trends began near the 6-month (halfway) mark of the study period. To account for this, we introduced an interaction term to calculate separate hazard ratios for periods 1 (Jan 1, 2022, to June 30, 2022) and 2 (July 1, 2022, to Dec 31, 2022) for those 4 covariates.

In Cox regression multivariable analysis (Table 2), increasing age was associated with reduced 129 hazard during this first period when controlling for other covariates. The greatest reduction in hazard 130 compared to the reference age group (18-39) was seen in the 80+ age group (HR 0.41 95% CI 0.36-0.46). 131 Similar but lower reductions were observed in the 60-79 (HR 0.44 95% CI 0.4-0.48) and 40-59 (HR 0.71 132 95% CI 0.66-0.76) age groups. A significant interaction between calendar time and the hazards for age was 133 found in each age group compared to the reference group (p < .001 for each). In the second half of the study 134 period, only the 60-79 age group demonstrated a significantly different hazard than the reference group 135 (HR 0.86, 95% CI 0.76-0.99). Trends in cumulative incidence stratified by number of comorbidities in are 136 137 observed in Fig. 1.

# Table 2: Multivariable analysis for hazard of breakthrough SARS-CoV-2 infection using Cox modeling.

|                                 |                                    |                                    |  | Covariate x<br>Period<br>Interaction |
|---------------------------------|------------------------------------|------------------------------------|--|--------------------------------------|
| Covariate                       | Hazard Ratio (95% CI),<br>Period 1 | Hazard Ratio (95% CI),<br>Period 2 | Hazard Ratio (95% CI),<br>Both Periods | Term Type 3<br>p-value               |
| Age Group                       |                                    |                                    |  | L                                    |
| 18-39                           | Ref                                | Ref                                | Ref                                    |                                      |
| 40-59                           | 0.712 (0.664, 0.763) *             | 0.921 (0.809, 1.049)               | 0.751 (0.706, 0.798) *                 | < .001                               |
| 60-79                           | 0.442 (0.409, 0.477) *             | 0.863 (0.756, 0.985) *             | 0.529 (0.496, 0.565) *                 | <.001                                |
| 80+                             | 0.406 (0.359, 0.459) *             | 0.953 (0.800, 1.136)               | 0.522 (0.472, 0.576) *                 | <.001                                |
| Male                            | Ref                                | Ref                                | Ref                                    |                                      |
| Female                          |                                    |                                    | 1.010 (0.964, 1.058)                   |                                      |
| Race                            |                                    |                                    |  |                                      |
| White                           | Ref                                | Ref                                | Ref                                    |                                      |
| Asian                           | 1.320 (1.190, 1.463) *             | 1.232 (1.028, 1.476) *             | 1.305 (1.193, 1.428)                   | .517                                 |
| Black or African<br>American    | 0.828 (0.734, 0.935) *             | 1.164 (1.003, 1.351) *             | 0.945 (0.861, 1.038)                   | < .001                               |
| Other                           | 0.944 (0.836, 1.068)               | 0.987 (0.816, 1.193)               | 0.959 (0.862, 1.067)                   | .691                                 |
| Not Hispanic,<br>Latino, or     |                                    |                                    |  |                                      |
| Spanish                         |                                    |                                    | Ref                                    |                                      |
| Hispanic, Latino,<br>or Spanish |                                    |                                    | 1.480 (1.354, 1.618) *                 |                                      |
| Weeks from                      |                                    |                                    |  |                                      |
| Booster to study<br>start       | 1.034 (1.027, 1.040) *             | 1.013 (1.002, 1.023) *             | 1.028 (1.023, 1.033) *                 | < .001                               |
| Number of Comor                 | bidities                           | 1                                  |  |                                      |

| 0  | Ref                    | Ref                    | Ref                    |        |
|--|------------------------|------------------------|------------------------|--------|
| 1  | 1.009 (0.938, 1.087)   | 1.271 (1.110, 1.455) * | 1.057 (0.991, 1.127)   | .003   |
| 2  | 1.022 (0.940, 1.109)   | 1.449 (1.260, 1.665) * | 1.108 (1.033, 1.189) * | < .001 |
| 3+   | 1.163 (1.075, 1.258) * | 1.726 (1.513, 1.969) * | 1.288 (1.205, 1.377) * | < .001 |
| *p < .05   |                        |                        |                        |        |
| Period 1 = January 1, 2022, to June 30, 2022, Period 2 = July 1, 2022, to Dec 31, 2022 |                        |                        |                        |        |

140

# Fig. 1 Cumulative incidence curve for COVID-19 breakthrough infection by age when stratified by number of comorbidities (per panel).

143

Cox regression modeling (Table 2) also revealed an increased hazard for those of Asian race 144 compared to the reference group (white race) in both periods (period 1: HR 1.32 95% CI 1.19-1.46; period 145 146 2 HR 1.23 95% CI 1.03-1.48). Significant associations with hazard were seen in the Black or African 147 American race group compared to the reference group, though the directions of these associations differed between study periods (period 1: HR 0.83 95% CI 0.73-0.94; period 2: HR 1.16 95% CI 1.03-1.48). People 148 of Hispanic, Latino, or Spanish ethnicity also had a higher hazard for COVID-19 breakthrough infection 149 compared to those not in that ethnic group (HR 1.48 95% CI 1.35-1.62). Days from booster to start of study 150 showed an increased hazard of 1.03 per week (95% CI 1.03-1.04) and later 1.01 per week (95% CI 1.00-151 1.02). The interaction term for calendar time and this variable was significant (p < .001). 152

153 Compared to having none, having one or two comorbidities was not significantly associated with 154 increased hazard for Omicron infection during period 1 when controlling for other variables. In contrast, 155 having three or more comorbidities was associated with increased hazard for breakthrough (HR=1.16 CI 156 1.08-1.26). During the second half of the study, having one comorbidity (HR = 1.27 95% CI 1.11-1.46), 157 having two comorbidities (HR= 1.45 95% CI 1.26-1.67) and having three or more comorbidities (HR 1.73, 158 95% CI 1.51-1.97) were all associated with increased hazard for Omicron breakthrough compared to those

with no comorbidities. Cumulative incidence over time between co-morbidity groups and stratified by age
 category are presented in Fig. 2. Cumulative incidence over time between age categories and stratified by
 co-morbidities groups are presented in Fig. 1.

Fig. 2 Cumulative incidence curve for COVID-19 breakthrough infection by number of comorbidities
 when stratified by age category (per panel).

### 164 **Discussion**

In this large cohort study across an urban healthcare system in Chicago, we found that omicron 165 breakthrough infections were common with a one-year cumulative incidence of 5.1% for all vaccinated and 166 boosted individuals. We observed a higher incidence of breakthrough infections among individuals with 167 multiple comorbidities and those who had a longer time since vaccine booster. However, age was also an 168 169 important factor with increasing age independently associated with reduced risk of Omicron breakthrough likely due to less risk taking and lower exposure among the highest age groups. We found racial and Ethnic 170 differences in infection incidence as demonstrated by increased risk of Omicron breakthrough for 171 individuals identifying as Asian race or Hispanic/Latino ethnicity, again likely due to differences in 172 173 exposure from social behaviors rather than inherent immunogenetic differences. Perhaps our most intriguing finding was that across all age groups, those with three or more co-morbidities had the highest 174 incidence of SARS-CoV-2 infection, and this factor did not appear to alter individual behavior to lower 175 exposure as much as age. The immune effects of co-morbidity might have overwhelmed any decrease in 176 social behavior risk related exposure. Thus, acquisition of Omicron SARS-CoV-2 was complex with 177 behavioral and individual risk or immunologic factors driving SARS-CoV-2 infection despite vaccination. 178

Our findings are consistent with previous studies that have reported a significant burden of breakthrough infections despite vaccination efforts. For example, a study by Stouten et al. [14] found a similar cumulative incidence of 11.2% among vaccinated individuals in a different urban setting. Similarly, Sun et al.[15] reported an incidence of 7.1% in those without immune dysfunction and slightly higher rates

183 for those with specific diseases affecting the immune system. Our cumulative incidence is lower than the ones reported in these studies. This likely relates to several factors including study population, 184 methodologic differences, and SAR-CoV-2 variant circulating during the study period. The predominant 185 circulating variant of concern in prior studies was the Delta variant, which has been the most studied in 186 187 terms of breakthrough and consistently demonstrated high incidence rates [16]. Additionally, studies conducted in rural populations have demonstrated lower incidence of breakthrough [17, 18]. One study in 188 a small cohort in New York City reported an incidence <1% [19], but this discrepancy is likely due to study 189 time period and significantly smaller sample size compared to our study and others with higher incidence. 190 191 As expected, and generally observed, evidence suggests that breakthrough infections are common across many different populations and healthcare settings and may vary with overtime with shifts in vaccine 192 coverage, population immunity, and circulating SARS-CoV-2 variant strain. 193

194 Our study revealed an intriguing finding in that having three or more comorbid diseases heightened the risk of breakthrough infections across all age groups. Having more comorbidities increases risk of infection 195 196 greater than one would expect of the individual comorbidities. Surprisingly, this heightened risk did not seem to prompt significant alterations in individual behavior. It is plausible that the impact of these 197 comorbidities on immunity overshadowed any potential behavioral changes. Alternatively, it could be that 198 199 comorbidities are not as influential in driving behavioral and lifestyle changes as age. However, the latter would contrast with prior studies suggesting that perceived vulnerability and severity, along with self-200 201 efficacy and intention, are drivers of COVID-19 protective behaviors[20-23]. Our findings align with those of Smits et al. [24], who examined four specific comorbidities and observed that patients with two or more 202 203 of these conditions also faced a greater risk than would be expected based on the individual effects of each comorbidity. This contrasts with the findings of Walmsley et al. [25], who did not identify significant 204 205 variations in the rate of breakthrough infections among individuals with underlying comorbidities. Theses investigators acknowledged that this discrepancy may be due to the low number of participants with 206 comorbid diseases in their study, which could have hindered the identification of a clear association. 207

208 Immune compromising co-morbidities have been shown to increase risk of SARS-CoV-2 infection [26];[27-29], however, we did not find any significant increased risk among those in our 209 immunocompromised groups of stem cell or solid organ transplant recipients as has been previously 210 reported[28]. Whether due to the impact on the immune system or lack of an effect on behaviors, our 211 212 findings reveal that independent of age or type of comorbidity, an increasing amount of comorbidity burden increased the risk for Omicron SARS-CoV-2 infection after vaccination within a population most 213 vulnerable to worse outcomes and severe COVID-19 disease. Thus, public health messing should continue 214 to emphasize the importance of infection prevention measures within this key group. 215

We noted that older individuals became at higher risk for infection at later time points, suggesting 216 reduction in vaccine response or increase in risk taking behaviors over time. This finding is consistent with 217 a previous study that demonstrated an inverse association between age and antibody titers only three months 218 219 after mRNA vaccination [30]. Similarly, a study focusing on immunocompromised individuals found that although vaccination was associated with a modest risk reduction, older individuals continued to have 220 higher rates of breakthrough SARS-CoV-2 infections [15]. Research has shown that as the immune system 221 ages, the number of naïve T and B cells decreases, which can lead to reduced vaccine efficiency and a 222 predisposition to breakthrough infections. While the quality of antibodies remains unaffected, aging is 223 224 associated with a decrease in the quantity of antibodies produced after vaccination, rendering individuals more susceptible to infection [31, 32]. Our results support prior evidence establishing that, independent of 225 226 comorbidities or immunocompromised status, increased age is a strong risk factor for breakthrough infection likely due to declining immunity over time. Overall, this evidence suggest that the diminished 227 quantity of antibodies produced in older individuals puts them at greater risk compared to the longer-lasting 228 229 protection seen in younger people. Our findings also support recent recommendations for SARS-CoV-2 230 vaccine boosting approximately twice per year among individuals over 65 years of age [33].

In contrast to our findings regarding older individuals, multiple studies have identified younger age as
a risk factor for COVID-19 breakthrough infection[14, 25, 34]. It's important to note that these studies

233 varied in design, cohort size, and follow-up duration, which may have influenced their ability to capture 234 current evolving trends. These findings align with our observations shortly after vaccination, where younger age emerged as an important risk factor. We attribute this phenomenon to social behaviors playing a larger 235 role than age during earlier time periods, when immunity has not yet significantly declined and vaccine 236 237 response more protective. Young adults engage in more social interactions and risk-taking behaviors for respiratory virus acquisition compared to the elderly, potentially increasing their exposure to SARS-CoV-238 2through daily activities [35, 36]. Certain occupations, such as healthcare work, transit operation, and retail 239 roles, have been identified as particularly high-risk for breakthrough infection despite full vaccination [37, 240 38]. Additionally, younger individuals may perceive themselves as less vulnerable to severe COVID-19 241 disease and therefore be more likely to disregard public health precautions such as social distancing and 242 mask-wearing, or they may be less adept at recognizing the signs and symptoms of the virus, leading to 243 further spread of the disease [39, 40]. Thus, it appears that prior to a significant decline in immunity and 244 vaccine efficacy, behaviors among younger individuals likely drive and risk for breakthrough SARS-Co-245 V2 infections. 246

Time since last booster dose and certain racial/ethnic group also emerged as independent risk factors. 247 A study described a similar finding in relation to the time since second vaccine dose [41]. This finding is 248 249 consistent with waning vaccine immunity that has been previously described [42-46]. Our study also highlights the increased risk of Omicron SARS-CoV-2 infection among vaccinated individuals from 250 251 Hispanic, Asian, and Black ethnic/racial groups. We believe it is unlikely that there is a biological basis to these associations- rather due to well-established socioeconomic factors known to play significant roles in 252 influencing the occurrence and outcomes of SARS-CoV-2 and COVID disease [47-49]. Prior studies 253 examining breakthrough SARS-CoV-2 infection do not comment on demographic information, likely 254 255 limited geographical regions being studied. [14, 16]. However, reports in immunocompromised populations did not find any significant racial or ethnic differences [15, 50]. Disparities in healthcare access and quality 256 may contribute to certain demographic groups facing a higher risk of SARS-CoV-2 infection[47, 51]. 257

Engagement in higher-risk occupations, larger household size, lower income level, distrust in healthcare, lack of health insurance, and unequal access to healthcare services are among the key contributors to these disparities [52]. Efforts to address these disparities and improve healthcare outcomes for high-risk demographic groups are needed and should include interventions aimed at expanding access to healthcare and insurance, establishing more equitable care models, and addressing the underlying social determinants of health.

Our study has several limitations that should be considered when interpreting the results. Firstly, our 264 research was conducted using electronic medical records within a single urban healthcare system, which 265 likely did not capture all breakthrough SARS-CoV-2 infections. Patients who sought care outside of our 266 NM system or opted for at-home testing were not always identified in our analysis, potentially leading to 267 an underestimation of the true cumulative incidence of breakthrough SARS-CoV-2 infections. 268 269 Additionally, mild, or asymptomatic breakthrough infections may be underreported in our study, as individuals with less severe symptoms might be less likely to seek medical care or testing. Secondly, given 270 our study population selection criteria (see above), we may have included individuals who were generally 271 more proactive about seeking healthcare services and thus may be overrepresented. This may affect the 272 generalizability of our findings to a broader less engaged population. Additionally, the findings of this study 273 274 may not be generalizable to other populations or healthcare settings. Factors such as population demographics, vaccination rates, and healthcare infrastructure can vary widely between different regions 275 276 and may impact the incidence and risk factors for breakthrough SARS-CoV-2 infections. Lastly, our study was conducted during a specific timeframe and primarily focused on the Omicron variant. The future 277 incidence and risk factors for breakthrough SARS-Co-2 infections will likely vary with evolving population 278 immunity (natural and/or updated vaccines) and changes in circulating immune evasive Omicron sub-279 280 variants. Despite these limitations, we studied a large population with nearly 8,000 breakthrough infection events during the Omicron era and were able to assess associations with key demographic and clinical 281 characteristics driving SARS-CoV-2 acquisition using strong statistical methods. 282

283

## 284 Conclusion

Our study sheds light on the complex interplay of factors influencing Omicron breakthrough infections 285 in a large urban healthcare system in Chicago among a population of SARS-CoV-2 vaccinated and boosted 286 individuals. We found a substantial one-year cumulative incidence of 5.1%, highlighting the ongoing 287 challenges posed by SARS-CoV-2 despite vaccination efforts. These findings reflect real-world differences 288 in immunity and exposure risk behaviors for populations vulnerable to Omicron variants of SARS-CoV-2 289 worldwide. By identifying key risk factors and disparities, our findings can inform targeted public health 290 291 interventions to mitigate the impact of breakthrough infections in vaccinated populations. Public health messages should continue to emphasize the importance of considering both co-morbidities and age as 292 critical factors in understanding and mitigating the risk of SARS-CoV-2 acquisition, ensuring that 293 interventions are tailored to address the specific needs of vulnerable populations. As people make decisions 294 about booster vaccinations, our findings provide more information for patients to consider personal risk in 295 their decision making. Ongoing public health surveillance and research are crucial to understand the long-296 term effectiveness of vaccines against SARS-CoV-2. Future research should focus on understanding 297 298 mechanisms of declining immunity, immune evasion by SARS-CoV-2 viruses, drivers of acquisition behavior, and optimizing protective vaccine. 299

## **Financial Disclosures**

Research reported in this publication was supported, in part, by the National Institutes of Health's National Center for Advancing Translational Sciences (grant number UL1TR001422) which supports the Northwestern Medicine Enterprise Data Warehouse. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research reported

in this publication was also supported by the Division of Infectious Diseases emerging and re-emerging
 pathogens program (EREPP) at the Northwestern University Feinberg School of Medicine

## **307 References**

Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and Efficacy of the
 NVX-CoV2373 COVID-19 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized
 Controlled Trial. Clin Infect Dis. 2022. Epub 20221010. doi: 10.1093/cid/ciac803. PubMed PMID:
 36210481.

Thomas SJ, Moreira ED, Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and
 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med.
 2021;385(19):1761-73. Epub 20210915. doi: 10.1056/NEJMoa2110345. PubMed PMID: 34525277;
 PubMed Central PMCID: PMCPMC8461570.

Lewis NM, Self WH, Gaglani M, Ginde AA, Douin DJ, Keipp Talbot H, et al. Effectiveness of the
 Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing
 COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. Clin Infect Dis.
 2022;75(Supplement\_2):S159-S66. doi: 10.1093/cid/ciac439. PubMed PMID: 35675695; PubMed Central
 PMCID: PMCPMC9214149.

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine
 BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594-9. Epub
 20200930. doi: 10.1038/s41586-020-2814-7. PubMed PMID: 32998157.

Haggenburg S, Lissenberg-Witte BI, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate
 NJE, et al. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised
 adult hematology patients. Blood Adv. 2022;6(5):1537-46. doi: 10.1182/bloodadvances.2021006917.
 PubMed PMID: 35114690; PubMed Central PMCID: PMCPMC8816838.

Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Nesher L, Stein M, et al.
BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19

- patients in Israel. Clin Microbiol Infect. 2021;27(11):1652-7. Epub 20210707. doi:
  10.1016/j.cmi.2021.06.036. PubMed PMID: 34245907; PubMed Central PMCID: PMCPMC8261136.
- 332 7. Islam JY, Vidot DC, Havanur A, Camacho-Rivera M. Preventive Behaviors and Mental Health-
- 333 Related Symptoms Among Immunocompromised Adults During the COVID-19 Pandemic: An Analysis of
- the COVID Impact Survey. AIDS Res Hum Retroviruses. 2021;37(4):304-13. doi:
- 10.1089/AID.2020.0302. PubMed PMID: 33626959; PubMed Central PMCID: PMCPMC8035912.
- 8. Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States: Center for

337 Disease Control and Prevention 2023 [updated January, 2024]. Available from:

338 <u>https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html</u>.

339 9. Starren JB, Winter AQ, Lloyd-Jones DM. Enabling a Learning Health System through a Unified

340 Enterprise Data Warehouse: The Experience of the Northwestern University Clinical and Translational

341 Sciences (NUCATS) Institute. Clin Transl Sci. 2015;8(4):269-71. Epub 20150601. doi: 10.1111/cts.12294.

PubMed PMID: 26032246; PubMed Central PMCID: PMCPMC4553136.

Fox J. An R Companion to Applied Regression. Third ed. Thousand Oaks, CA: Sage Publications;
2019.

11. T T. A Package for Survival Analysis in R. R package version 3.5-5,2023.

Terry M. Therneau PMG. Modeling Survival Data : Extending the Cox Model. Springer, New York
2000.

13. Sjoberg DD FT. Competing Risks Estimation. R package version 0.2.0. 2022.

349 14. Stouten V, Hubin P, Haarhuis F, van Loenhout JAF, Billuart M, Brondeel R, et al. Incidence and

350 Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium.

351 Viruses. 2022;14(4). Epub 20220413. doi: 10.3390/v14040802. PubMed PMID: 35458532; PubMed

- 352 Central PMCID: PMCPMC9029338.
- Sun J, Zheng Q, Madhira V, Olex AL, Anzalone AJ, Vinson A, et al. Association Between Immune
  Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. JAMA

Intern Med. 2022;182(2):153-62. doi: 10.1001/jamainternmed.2021.7024. PubMed PMID: 34962505;
PubMed Central PMCID: PMCPMC8715386.

Gopinath S, Ishak A, Dhawan N, Poudel S, Shrestha PS, Singh P, et al. Characteristics of COVIDBreakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic
Review. Trop Med Infect Dis. 2022;7(5). Epub 20220522. doi: 10.3390/tropicalmed7050081. PubMed
PMID: 35622708; PubMed Central PMCID: PMCPMC9144541.

17. COVID-19 Stats: COVID-19 Incidence,\* by Urban-Rural Classification(dagger) - United States,
January 22-October 31, 2020( section sign). MMWR Morb Mortal Wkly Rep. 2020;69(46):1753. Epub
20201120. doi: 10.15585/mmwr.mm6946a6. PubMed PMID: 33211682; PubMed Central PMCID:
PMCPMC7676636.

Fazili A, Ain SN, Shah RJ, Raja FN, Farhat D, Nazir I. Incidence of breakthrough infections after
 COVID-19 vaccination among the COVID-19 vaccine recipients at a Tertiary Care Hospital in Srinagar.

367 Indian J Public Health. 2023;67(2):305-8. doi: 10.4103/ijph.ijph\_1403\_22. PubMed PMID: 37459029.

Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, et al. Vaccine Breakthrough
Infections with SARS-CoV-2 Variants. N Engl J Med. 2021;384(23):2212-8. Epub 20210421. doi:

10.1056/NEJMoa2105000. PubMed PMID: 33882219; PubMed Central PMCID: PMCPMC8117968.

Yazdanpanah M, Abadi B, Komendantova N, Zobeidi T, Sieber S. Some at Risk for COVID-19
Are Reluctant to Take Precautions, but Others Are Not: A Case From Rural in Southern Iran. Front Public
Health. 2020;8:562300. Epub 20201116. doi: 10.3389/fpubh.2020.562300. PubMed PMID: 33304873;
PubMed Central PMCID: PMCPMC7701237.

Kukreti S, Hsieh MT, Liu CH, Chen JS, Chen YJ, Hsieh MT, et al. Fear, Stress, Susceptibility, and 375 21. Problematic Social Media Use Explain Motivation for COVID-19 Preventive Behaviors Among Patients 376 Their With Stroke and Caregivers. Inquiry. 2024;61:469580231225030. doi: 377 10.1177/00469580231225030. PubMed PMID: 38314649; PubMed Central PMCID: PMCPMC10845975. 378 379 22. Mihelic A, Jelovcan L, Prislan K. Internal and external drivers for compliance with the COVID-19 preventive measures in Slovenia: The view from general deterrence and protection motivation. PLoS One. 380

2021;16(11):e0259675. Epub 20211115. doi: 10.1371/journal.pone.0259675. PubMed PMID: 34780530;
PubMed Central PMCID: PMCPMC8592422.

Bashirian S, Jenabi E, Khazaei S, Barati M, Karimi-Shahanjarini A, Zareian S, et al. Factors
associated with preventive behaviours of COVID-19 among hospital staff in Iran in 2020: an application of
the Protection Motivation Theory. J Hosp Infect. 2020;105(3):430-3. Epub 20200428. doi:
10.1016/j.jhin.2020.04.035. PubMed PMID: 32360337; PubMed Central PMCID: PMCPMC7194681.

387 24. Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, et al. Risk

of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine.

2023;41(15):2447-55. Epub 20230216. doi: 10.1016/j.vaccine.2023.02.038. PubMed PMID: 36803895;

390 PubMed Central PMCID: PMCPMC9933320.

391 25. Walmsley S, Nabipoor M, Lovblom LE, Ravindran R, Colwill K, McGeer A, et al. Predictors of

Breakthrough SARS-CoV-2 Infection after Vaccination. Vaccines (Basel). 2023;12(1). Epub 20231228.

393 doi: 10.3390/vaccines12010036. PubMed PMID: 38250849; PubMed Central PMCID:
394 PMCPMC10820583.

Willicombe M, Scanlon M, Loud F, Lightstone L. Should we be clinically assessing antibody
responses to covid vaccines in immunocompromised people? BMJ. 2022;377:o966. Epub 20220412. doi:
10.1136/bmj.o966. PubMed PMID: 35414604.

Hansen CH, Michlmayr D, Gubbels SM, Molbak K, Ethelberg S. Assessment of protection against
reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a populationlevel observational study. Lancet. 2021;397(10280):1204-12. Epub 20210317. doi: 10.1016/S01406736(21)00575-4. PubMed PMID: 33743221; PubMed Central PMCID: PMCPMC7969130.

Liu C, Lee J, Ta C, Soroush A, Rogers JR, Kim JH, et al. Risk Factors Associated With SARSCoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis. JMIR
Public Health Surveill. 2022;8(5):e35311. Epub 20220524. doi: 10.2196/35311. PubMed PMID:
35486806; PubMed Central PMCID: PMCPMC9132195.

| 406 | 29. White EM, Yang X, Blackman C, Feifer RA, Gravenstein S, Mor V. Incident SARS-CoV-2     |
|-----|--|
| 407 | Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents. N Engl J Med.     |
| 408 | 2021;385(5):474-6. Epub 20210519. doi: 10.1056/NEJMc2104849. PubMed PMID: 34010526; PubMed |
| 409 | Central PMCID: PMCPMC8174028.  |
|     |  |

- 410 30. O'Rourke K. Age and smoking predict antibody titers after the BNT162b2 COVID-19 vaccine.
- 411 Cancer. 2022;128(3):431. doi: 10.1002/cncr.34082. PubMed PMID: 35050525; PubMed Central PMCID:
  412 PMCPMC9015587.
- 413 31. Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E. SARS-CoV-2,
- 414 COVID-19 and the Ageing Immune System. Nat Aging. 2021;1(9):769-82. Epub 20210914. doi:
- 415 10.1038/s43587-021-00114-7. PubMed PMID: 34746804; PubMed Central PMCID: PMCPMC8570568.
- 416 32. Blomberg BB, Frasca D. Quantity, not quality, of antibody response decreased in the elderly. J Clin
- 417 Invest. 2011;121(8):2981-3. Epub 20110725. doi: 10.1172/JCI58406. PubMed PMID: 21785210; PubMed
- 418 Central PMCID: PMCPMC3148749.
- 419 33. CDC. nterim Clinical Considerations for Use of COVID-19 Vaccines in the United States Centers
- 420 for Disease and Control Prevention2024. Available from: <u>https://www.cdc.gov/vaccines/covid-19/clinical-</u>
- 421 <u>considerations/interim-considerations-</u>
- 422 <u>us.html#:~:text=Summary%20of%20recent%20changes%20(last,Novavax%2C%20Pfizer%2DBioNTech</u>
- 423 <u>).C</u>.

34. Dash NR, Barqawi HJ, Obaideen AA, Al Chame HQ, Samara KA, Qadri R, et al. COVID-19
Breakthrough Infection Among Vaccinated Population in the United Arab Emirates. J Epidemiol Glob
Health. 2023;13(1):67-90. Epub 20230216. doi: 10.1007/s44197-023-00090-8. PubMed PMID: 36795274;
PubMed Central PMCID: PMCPMC9933808.

- 428 35. Wilson RF, Sharma AJ, Schluechtermann S, Currie DW, Mangan J, Kaplan B, et al. Factors
- 429 Influencing Risk for COVID-19 Exposure Among Young Adults Aged 18-23 Years Winnebago County,
- 430 Wisconsin, March-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(41):1497-502. Epub 20201016.

431 doi: 10.15585/mmwr.mm6941e2. PubMed PMID: 33056953; PubMed Central PMCID:
432 PMCPMC7561092.

36. Rolison JJ, Hanoch Y, Wood S, Liu PJ. Risk-taking differences across the adult life span: a question
of age and domain. J Gerontol B Psychol Sci Soc Sci. 2014;69(6):870-80. Epub 20131022. doi:
10.1093/geronb/gbt081. PubMed PMID: 24149517.

Malhotra S, Mani K, Lodha R, Bakhshi S, Mathur VP, Gupta P, et al. SARS-CoV-2 Reinfection
Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection
Among Health Care Workers in New Delhi, India. JAMA Netw Open. 2022;5(1):e2142210. Epub
20220104. doi: 10.1001/jamanetworkopen.2021.42210. PubMed PMID: 34994793; PubMed Central
PMCID: PMCPMC8742193.

441 38. de Gier B, de Oliveira Bressane Lima P, van Gaalen RD, de Boer PT, Alblas J, Ruijten M, et al.
442 Occupation- and age-associated risk of SARS-CoV-2 test positivity, the Netherlands, June to October 2020.

Euro Surveill. 2020;25(50). doi: 10.2807/1560-7917.ES.2020.25.50.2001884. PubMed PMID: 33334396;
PubMed Central PMCID: PMCPMC7812419.

39. Rumain B, Schneiderman M, Geliebter A. Prevalence of COVID-19 in adolescents and youth
compared with older adults in states experiencing surges. PLoS One. 2021;16(3):e0242587. Epub
20210310. doi: 10.1371/journal.pone.0242587. PubMed PMID: 33690600; PubMed Central PMCID:
PMCPMC7946189.

40. Schneiderman M, Rumain B, Kaganovskiy L, Geliebter A. Incidence and Relative Risk of COVID19 in Adolescents and Youth Compared With Older Adults in 19 US States, Fall 2020. JAMA Netw Open.
2022;5(7):e2222126. Epub 20220701. doi: 10.1001/jamanetworkopen.2022.22126. PubMed PMID:
35838670; PubMed Central PMCID: PMCPMC9287748.

41. McKeigue PM, McAllister DA, Hutchinson SJ, Robertson C, Stockton D, Colhoun HM. Vaccine
efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in
patients in Scotland (REACT-SCOT): a case-control study. Lancet Respir Med. 2022;10(6):566-72. Epub

22

456 20220225. doi: 10.1016/S2213-2600(22)00045-5. PubMed PMID: 35227416; PubMed Central PMCID:
457 PMCPMC8880999.

Lim SY, Kim JY, Jung J, Yun SC, Kim SH. Waning of humoral immunity depending on the types 42. 458 COVID-19 vaccine. Infect Dis (Lond). 2023;55(3):216-20. 20230110. 459 of Epub doi: 460 10.1080/23744235.2023.2165707. PubMed PMID: 36625442.

43. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine
Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022;386(16):1532-46. Epub
20220302. doi: 10.1056/NEJMoa2119451. PubMed PMID: 35249272; PubMed Central PMCID:
PMCPMC8908811.

465 44. Tan WC, Tan JYJ, Lim JSJ, Tan RYC, Lee A, Leong FL, et al. COVID-19 Severity and Waning
466 Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched
467 Controls in Singapore: A Nationwide Cohort Study. JAMA Oncol. 2023;9(9):1221-9. doi:
468 10.1001/jamaoncol.2023.2271. PubMed PMID: 37440245; PubMed Central PMCID: PMCPMC10346511.
45. Intawong K, Chariyalertsak S, Chalom K, Wonghirundecha T, Kowatcharakul W, Thongprachum

A, et al. Waning vaccine response to severe COVID-19 outcomes during omicron predominance in
Thailand. PLoS One. 2023;18(5):e0284130. Epub 20230511. doi: 10.1371/journal.pone.0284130. PubMed
PMID: 37167215; PubMed Central PMCID: PMCPMC10174527.

46. Feng A, Obolski U, Stone L, He D. Modelling COVID-19 vaccine breakthrough infections in
highly vaccinated Israel-The effects of waning immunity and third vaccination dose. PLOS Glob Public
Health. 2022;2(11):e0001211. Epub 20221109. doi: 10.1371/journal.pgph.0001211. PubMed PMID:
36962648; PubMed Central PMCID: PMCPMC10021336.

477 47. Khanijahani A, Iezadi S, Gholipour K, Azami-Aghdash S, Naghibi D. A systematic review of
478 racial/ethnic and socioeconomic disparities in COVID-19. Int J Equity Health. 2021;20(1):248. Epub
479 20211124. doi: 10.1186/s12939-021-01582-4. PubMed PMID: 34819081; PubMed Central PMCID:
480 PMCPMC8611382.

481 48. Spruce L. Back to Basics: Social Determinants of Health. AORN J. 2019;110(1):60-9. doi:
482 10.1002/aorn.12722. PubMed PMID: 31246307.

483 49. Abrams EM, Szefler SJ. COVID-19 and the impact of social determinants of health. Lancet Respir
484 Med. 2020;8(7):659-61. Epub 20200518. doi: 10.1016/S2213-2600(20)30234-4. PubMed PMID:
485 32437646; PubMed Central PMCID: PMCPMC7234789.

50. Sun J, Patel RC, Zheng Q, Madhira V, Olex AL, Islam JY, et al. COVID-19 Disease Severity among People with HIV Infection or Solid Organ Transplant in the United States: A Nationallyrepresentative, Multicenter, Observational Cohort Study. medRxiv. 2021. Epub 20210728. doi:

489 10.1101/2021.07.26.21261028. PubMed PMID: 34341798; PubMed Central PMCID: PMCPMC8328066.

490 51. Agyemang C, Richters A, Jolani S, Hendriks S, Zalpuri S, Yu E, et al. Ethnic minority status as

491 social determinant for COVID-19 infection, hospitalisation, severity, ICU admission and deaths in the early

492 phase of the pandemic: a meta-analysis. BMJ Glob Health. 2021;6(11). doi: 10.1136/bmjgh-2021-007433.

493 PubMed PMID: 34740916; PubMed Central PMCID: PMCPMC8573300.

494 52. Lopez L, 3rd, Hart LH, 3rd, Katz MH. Racial and Ethnic Health Disparities Related to COVID-19.

495 JAMA. 2021;325(8):719-20. doi: 10.1001/jama.2020.26443. PubMed PMID: 33480972.

496

## 497 **Supporting Information**

- 498 S1 Dataset. Vaccine Cohort Dataset.
- 499 S2 Supporting Information. Vaccine Cohort Dataset Codebook


500

## **Breakthrough Infection by Age and Comorbidities**

18-39 40-59 60-79 80+ Age

## No Comorbidities

1 Comorbidity







Figure 1

## **Breakthrough Infection by Comorbidities and Age**

Comorbidities 0 1 2 3+






Figure 2